Yaron Eldad - 18 Mar 2026 Form 3 Insider Report for Evogene Ltd. (EVGN)

Role
Chief Financial Officer
Signature
/s/ Nitsan Deutsch, attorney-in-fact
Issuer symbol
EVGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 08:09:07 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ELDAD YARON Chief Financial Officer 30 HAIRIT ST., MAALE ADUMIM, ISRAEL /s/ Nitsan Deutsch, attorney-in-fact 18 Mar 2026 0001408407

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EVGN Ordinary shares 4,100 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 15,000 $12.58 Direct F2
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 60,000 $2.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
F2 The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.
F3 The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.